The ophthalmology equipment company completed nearly 100 million yuan round of financing, will accelerate product development.

Pharmaceutical Network Enterprise News it is understood that Aikangt Medical Technology Co., Ltd. ("Aiconte") recently completed nearly 100 million yuan A round of financing, and has locked in the A-round financing.
the current round of financing by Sequoia Capital China, Sherba Investment, Fosun Ventures, Songyu Capital, Yuansheng Ventures, Hengqin Jin Investment and other co-investments.
the current round of financing will be used to accelerate the development, clinical and registration process of Aconte's many eye-optical medical device products.
public information shows that Aiconte is committed to the field of ophthalmology ophthalmology medical devices a full set of innovative solutions for research and development, its eye vision solutions mainly related to juvenile myopia prevention and control, adult vision correction and eye surface disease treatment, contact lens complete set of care products and eye vision inspection equipment.
look at Aiconte's product line, including corneal plastic mirrors (OK mirrors) and multi-focus corneal contact lenses for adolescent myopia prevention and control.
the current market penetration rate of OK mirror less than 2%, but the overall market size of 2 billion, and more than 20% growth rate to achieve high growth.
And multi-focus corneal contact lenses are suitable for highly myopic asthras users or patients who are not suitable for night-wearing OK mirrors, the market is still in its early stages, and Eaconte expects that multi-focus corneal contact lenses will cover 15% of the youth myopia prevention and control market in the future.
, who is in charge of the company, said, "For this round of financing, Aiconte is very pleased to have the capital to endorse and support us."
for adult vision correction and eye surface diseases, Aicont's next step will be to introduce corneal contact lenses and the country's first sclering mirror products, hoping to help more patients.
" is known that for adult vision correction and eye surface disease, Aiconte will soon launch corneal contact lenses and the country's first sclering mirror products, the latter will be expected to fill the gaps in the domestic industry.
addition, the company is currently opening a full range of contact lenses care product line and eye light-related inspection equipment two new business segments.
sequoia Capital, a new investor, was founded in 1972 and has nearly 30 funds with total managed capital of more than $10 billion.
Sequoia Capital China Fund currently manages a total of about $2.5 billion and a total of more than Rmb4bn in eight-phase funds to invest in high-growth companies in China.
Sequoia focuses on four directions: technology/media, consumer goods/services, healthcare, new energy/environmental protection/, etc., but the companies invested are not limited to this.
, the ophthalmology equipment track is being favored by the industry.
According to the National Visual Health Report, the incidence of myopia among people over 5 years of age will increase to 50.86% to 51.36% in 2020, and the number of people with the disease will be close to 704 million to 711 million, of which the number of people with high myopia will exceed 40 million.
data show that the number of nears sight in the country has exceeded 600 million, equivalent to one in every two to three is myopia, and the rate of myopia among adolescents remains high.
The White Paper on Chinese Eye Health shows that the overall rate of myopia among college students in China exceeds 90%, and the overall rate of children and adolescents is 53.6%.
according to the China Medical Device Industry Development Report compiled by the Forward-Looking Industry Research Institute, the domestic ophthalmology medical device market is large and growing fast, but foreign products account for a relatively high proportion.
the domestic ophthalmology medical device market will grow from 19 billion yuan in 2017 to 37.5 billion yuan by 2021, with a compound annual growth rate of 18.5 percent.
With the continuous upgrading of China's medical consumption level, and the increase in rectifier prevalence and cataract surgery rate, as well as femt second surgery, retinal services, corneal shape mirrors, artificial crystals and other new surgical development, the industry believes that the future of China's ophthalmology gold track is expected to usher in rapid development.
.